Liana Tsenova
Overview
Explore the profile of Liana Tsenova including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
1954
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tsenova L, Fallows D, Kolloli A, Singh P, OBrien P, Kushner N, et al.
Eur J Immunol
. 2020 Mar;
50(6):858-872.
PMID: 32130727
Host protective immunity against pathogenic Mycobacterium tuberculosis (Mtb) infection is variable and poorly understood. Both prior Mtb infection and BCG vaccination have been reported to confer some protection against subsequent...
2.
Tsenova L, Singhal A
J Pathol
. 2020 Feb;
250(5):636-646.
PMID: 32108337
Mycobacterium tuberculosis, the causative agent of tuberculosis (TB), has co-evolved with the human immune system and utilizes multiple strategies to persist within infected cells, to hijack several immune mechanisms, and...
3.
NLRP10 Enhances CD4 T-Cell-Mediated IFNγ Response Regulation of Dendritic Cell-Derived IL-12 Release
Vacca M, Bohme J, Zambetti L, Khameneh H, Paleja B, Laudisi F, et al.
Front Immunol
. 2017 Nov;
8:1462.
PMID: 29163529
NLRP10 is a nucleotide-binding oligomerization domain-like receptor that functions as an intracellular pattern recognition receptor for microbial products. Here, we generated a mouse to delineate the role of NLRP10 in...
4.
Cheng C, Gutierrez N, Marzuki M, Lu X, Foreman T, Paleja B, et al.
Sci Immunol
. 2017 Jul;
2(9).
PMID: 28707004
() executes a plethora of immune-evasive mechanisms, which contribute to its pathogenesis, limited efficacy of current therapy, and the emergence of drug-resistant strains. This has led to resurgence in attempts...
5.
Subbian S, Koo M, Tsenova L, Khetani V, Zeldis J, Fallows D, et al.
Front Immunol
. 2016 Jul;
7:238.
PMID: 27379099
The lengthy duration of multidrug therapy needed to cure tuberculosis (TB) poses significant challenges for global control of the disease. Moreover, chronic inflammation associated with TB leads to pulmonary damage...
6.
Subbian S, Tsenova L, Holloway J, Peixoto B, OBrien P, Dartois V, et al.
EBioMedicine
. 2016 Mar;
4:104-14.
PMID: 26981575
Objectives: Adjunctive host-directed therapy is emerging as a new potential approach to improve the outcome of conventional antimicrobial treatment for tuberculosis (TB). We tested the ability of a phosphodiesterase-4 inhibitor...
7.
Shatzkes K, Chae R, Tang C, Ramirez G, Mukherjee S, Tsenova L, et al.
Sci Rep
. 2015 Aug;
5:12899.
PMID: 26250699
Bdellovibrio spp. and Micavibrio spp. are Gram-negative predators that feed on other Gram-negative bacteria, making predatory bacteria potential alternatives to antibiotics for treating multi-drug resistant infections. While the ability of...
8.
Lesion-Specific Immune Response in Granulomas of Patients with Pulmonary Tuberculosis: A Pilot Study
Subbian S, Tsenova L, Kim M, Wainwright H, Visser A, Bandyopadhyay N, et al.
PLoS One
. 2015 Jul;
10(7):e0132249.
PMID: 26133981
The formation and maintenance of granulomas is central to the host response to Mycobacterium tuberculosis (Mtb) infection. It is widely accepted that the lungs of patients with tuberculosis (TB) usually...
9.
Singhal A, Jie L, Kumar P, Hong G, Leow M, Paleja B, et al.
Sci Transl Med
. 2014 Nov;
6(263):263ra159.
PMID: 25411472
The global burden of tuberculosis (TB) morbidity and mortality remains immense. A potential new approach to TB therapy is to augment protective host immune responses. We report that the antidiabetic...
10.
Etanercept exacerbates inflammation and pathology in a rabbit model of active pulmonary tuberculosis
Tsenova L, OBrien P, Holloway J, Peixoto B, Soteropoulos P, Fallows D, et al.
J Interferon Cytokine Res
. 2014 May;
34(9):716-26.
PMID: 24831609
Treatment of chronic inflammatory diseases with tumor necrosis factor alpha (TNF-α) antagonists has been associated with increased risk of tuberculosis (TB). We examined the usefulness of the rabbit model of...